Evidence map›Paper›PMID 39979252›Full record

ArticleNature communications2025

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.

Hitomi Hosoya, Mia Carleton, Kailee Tanaka, Brian Sworder, Shriya Syal, Bita Sahaf, Alisha M Maltos, Oscar Silva, Henning Stehr, Vanna Hovanky and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hitomi Hosoya *Division of Blood and Marrow Transplant and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA.
Mia Carleton *Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-9993-9787
Kailee TanakaDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Brian SworderDivision of Hematology/Oncology, Department of Medicine, University of California, Irvine CA, USA.
Shriya SyalCenter for Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Bita SahafCenter for Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA.
Alisha M MaltosDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-6631-481X
Oscar SilvaDepartment of Pathology, Stanford University, Stanford, CA, USA.
Henning StehrDepartment of Pathology, Stanford University, Stanford, CA, USA.
Vanna HovankyDivision of Blood and Marrow Transplant and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA.
George DuranDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-2692-3906
Tian ZhangDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.
Michaela LiedtkeDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.
Sally AraiDivision of Blood and Marrow Transplant and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA.
David IberriDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.
David MiklosDivision of Blood and Marrow Transplant and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0717-4305
Michael S KhodadoustDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
Surbhi SidanaDivision of Blood and Marrow Transplant and Cell Therapy, Department of Medicine, Stanford University, Stanford, CA, USA. surbhi.sidana@stanford.edu.ORCID http://orcid.org/0000-0003-3288-7614
David M KurtzDivision of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA. dkurtz@stanford.edu.ORCID http://orcid.org/0000-0002-6382-4651

Funding

Institutional Career Development Core (KL2)KL2TR003143 · NCATS · STANFORD UNIVERSITY · PI ASCH, STEVEN M. · 2019 to 2023
$8.7M
Molecular Characterization and Personalized Approaches to Non-Hodgkin Lymphoma from Circulating Tumor DNAK08CA241076 · NCI · STANFORD UNIVERSITY · PI KURTZ, DAVID MATTHEW · 2019 to 2023
$957k
NCATS NIH HHS KL2 TR003143NCI NIH HHS K08 CA241076U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) K08CA241076
6 · The paper itself

Abstract

Despite advances in treatments, multiple myeloma (MM) remains an incurable cancer where relapse is common. We developed a circulating tumor DNA (ctDNA) approach in order to characterize tumor genomics, monitor treatment response, and detect early relapse in MM. By sequencing 412 specimens from 64 patients with newly diagnosed or relapsed/refractory disease, we demonstrate the correlation between ctDNA and key clinical biomarkers, as well as patient outcomes. We further extend our approach to simultaneously track CAR-specific cell-free DNA (CAR-cfDNA) in patients undergoing anti-BCMA CAR T-cell (BCMA-CAR) therapy. We demonstrate that ctDNA levels following BCMA-CAR inversely correlate with relative time to progression (TTP), and that measurable residual disease (MRD) quantified by peripheral blood ctDNA (ctDNA-MRD) was concordant with clinical bone marrow MRD. Finally, we show that ctDNA-MRD can anticipate clinical relapse and identify the emergence of genomically-defined therapy-resistant clones. These findings suggest multiple clinical uses of ctDNA for MM in molecular characterization and disease surveillance.

Indexed as

Circulating Tumor DNADrug Resistance, NeoplasmImmunotherapy, AdoptiveMultiple MyelomaAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualReceptors, Chimeric AntigenT-LymphocytesBiomarkers, TumorCirculating Tumor DNAReceptors, Chimeric Antigen

Identifiers

PMID39979252
PMCPMC11842827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.